Hims & Hers Health Inc shares climbed after Barclays analyst Glen Santangelo reiterated an Overweight rating and lifted the price target to $39 from $29. The revised target reflects increased confidence in the company's growth trajectory, driven by improving trends in the GLP-1 segment following a partnership with Novo Nordisk A/S on March 9, 2026.

Barclays Expects Renewed Strength In GLP-1 Segment

Barclays highlighted proprietary data showing improving demand signals. Website traffic rose 12% year-over-year in April and 35% year-over-year in May. Barclaycard data indicated a 16% month-over-month increase in transactions during May, while total spending climbed 14% month-over-month.

Rating and Price Target

The analyst's decision to raise the price target suggests a stronger bullish stance on the stock's performance. The Overweight rating implies that the stock is expected to outperform the broader market or its sector peers.

HIMS Stock: Key Levels And Momentum

Hims & Hers continues to trade well above its short-term trend markers. The stock sits about 30% above the 20-day simple moving average at $27.08 and roughly 34% above the 50-day simple moving average at $26.32. It also trades about 5% above the 200-day simple moving average at $33.39.

Momentum signals remain constructive, with the MACD positioned above its signal line and a positive histogram reflecting strengthening buying pressure. However, the stock is recovering from a difficult twelve-month stretch where it fell 42.39%, and it continues to trade under the influence of a death cross that appeared in December 2025.

• Key Resistance: $36.50 — A nearby pivot zone where sellers have previously stepped in.
• Key Support: $33.00 — A short-term floor near the 200-day region.

Hims & Hers shares were up 9.94% at $35.06 at the time of publication.

Hims & Hers Health Inc shares rose 5.37% to $31.77 on Tuesday, continuing a rebound from recent profit-taking following the appointment of a new chief medical officer. The recovery is supported by a broader market rally, as U.S. equities surged following a peace agreement between the United States and Iran that reopened the Strait of Hormuz shipping lane. Despite the gains, the stock remains in a longer-term repair phase, trading below its 200-day simple moving average (SMA) after a steep drawdown.

The company named Anant Vinjamoori as chief medical officer, highlighting his background in longevity medicine and preventive healthcare. The appointment strengthens the medical leadership bench, which now boasts more than 100 years of combined experience across weight loss, sexual health, hormone health, mental health, dermatology, and primary care. This strategic move aims to expand beyond episodic treatment into longer-duration customer relationships, where clinical credibility supports retention and expansion.

Technical Indicators and Key Levels

From a technical perspective, Hims & Hers is in "repair" mode. The stock is currently trading above its 20-day SMA ($26.14), 50-day SMA ($25.85), and 100-day SMA ($23.50). However, the persistence of a "death cross" established in December 2025, where the 50-day SMA fell below the 200-day SMA, keeps the broader bias cautious until longer-term averages are reclaimed.

Momentum is improving, with the Moving Average Convergence Divergence (MACD) above its signal line and a positive histogram, indicating easing downside pressure. Key resistance for the stock is identified at the $32.00 level, which aligns just below the 200-day SMA zone of $33.50, while key support sits at $30.00.

Company Overview

Hims & Hers, launched in 2017, operates a telehealth platform connecting patients with healthcare providers for conditions such as erectile dysfunction, hair loss, skin care, mental health, and weight loss. The platform offers generic, branded, and compounded prescription drugs, alongside over-the-counter medicines, cosmetics, and supplements. The company serves more than 2 million subscribers across all 50 states and select European markets, relying on direct-to-consumer payments rather than insurance.